Astrazeneca PLC (Spons. ADRs)
[WKN: 886715 | ISIN: US0463531089]
Aktienkurse
64,809$ 0,26%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid: Ask:
Reuters Kategorien
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

Update on Imfinzi ADJUVANT BR.31 trial

25 June 2024 Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by…

Imfinzi improved EFS and OS in bladder cancer

25 June 2024 Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA…

Pfizer: Neuer Adipositas-Deal

Der Pharma-Riesen Novo Nordisk und Eli Lilly haben dem wachsenden Markt für Adipositas-Medikamente weiter fest im Griff. Mit Übernahmen brachten…

Astrazeneca: Kursziel erhöht!

In der vergangenen Woche erreichte die Aktie von Astrazeneca ein neues Jahreshoch von 12.646,00 Britischen Pence und durchbrach damit den…

Acquisition of Fusion completed

05 June 2024 Acquisition of Fusion completed AstraZeneca today announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage…

Total Voting Rights

3 June 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the…

AstraZeneca: Neues Kursziel

New York (www.aktiencheck.de) - Rating-Update: Mark Purcell, Analyst von Morgan Stanley, stuft die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN:weiterhin mit…

Dato-DXd improved OS in nonsquamous lung cancer

This announcement contains inside information 27 May 2024 Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small…